Literature DB >> 20045149

Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients.

Dirk von Lewinski1, Peter P Rainer, Robert Gasser, Marie-Sophie Huber, Mounir Khafaga, Bastian Wilhelm, Tobias Haas, Heinrich Mächler, Ulrich Rössl, Burkert Pieske.   

Abstract

Insulin causes inotropic effects via Ca(2+)-dependent and Ca(2+)-independent pathways. The latter one is potentially glucose dependent. We examined inotropic responses and signal transduction of insulin in human atrial myocardium of diabetic and nondiabetic patients to test for the role of glucose transporters. Experiments were performed in isolated atrial myocardium of 88 patients undergoing cardiac surgery and 28 ventricular muscle samples of explanted hearts. Influence of insulin (0.02 micromol/L) on isometric twitch force was examined with and without blocking glucose transporter (GLUT) 4 translocation (latrunculin), sodium-coupled glucose transporter (SGLT) 1 (phlorizin, T-1095A), or PI3-kinase (wortmannin). Experiments were performed in Tyrode solution containing glucose or pyruvate as energetic substrate. Messenger RNA expression of glucose transporters (GLUT1, GLUT4, SGLT1, SGLT2) was analyzed in atrial and ventricular myocardium of both diabetic and nondiabetic patients. Developed force increases after insulin (to 117.8% +/- 2.4% and 115.8% +/- 1.9%) in trabeculae from patients with and without diabetes. Inotropic effect was reduced after displacing glucose with pyruvate as well as after PI3-kinase inhibition (to 103% +/- 2%) or inhibition of glucose transporters GLUT4 (to 105% +/- 2%) and SGLT1 (phlorizin to 106% +/- 2%, T-1095A to 105% +/- 2%), without differences between the 2 groups. In glucose-free pyruvate-containing solution, only inhibition of PI3-kinase but not blocking glucose transporters resulted in further inhibitory effects. Messenger RNA expression did not show significant differences between patients with or without diabetes. Insulin exerts positive inotropic effects in human atrial myocardium. These effects are mediated via a PI3-kinase-sensitive and a glucose-transport-sensitive pathway. Differences in functional effects or messenger RNA expression of glucose transporters were not detectable between patients with and without diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20045149     DOI: 10.1016/j.metabol.2009.10.025

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  18 in total

Review 1.  Energetics and metabolism in the failing heart: important but poorly understood.

Authors:  Aslan T Turer; Craig R Malloy; Christopher B Newgard; Mihai V Podgoreanu
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-07       Impact factor: 4.294

Review 2.  SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

Authors:  Ele Ferrannini; Anna Solini
Journal:  Nat Rev Endocrinol       Date:  2012-02-07       Impact factor: 43.330

Review 3.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.

Authors:  Guanghong Jia; Michael A Hill; James R Sowers
Journal:  Circ Res       Date:  2018-02-16       Impact factor: 17.367

4.  Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats.

Authors:  N N Hamouda; V Sydorenko; M A Qureshi; J M Alkaabi; M Oz; F C Howarth
Journal:  Mol Cell Biochem       Date:  2014-10-29       Impact factor: 3.396

5.  Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart.

Authors:  Ivana Vrhovac; Daniela Balen Eror; Dirk Klessen; Christa Burger; Davorka Breljak; Ognjen Kraus; Nikola Radović; Stipe Jadrijević; Ivan Aleksic; Thorsten Walles; Christoph Sauvant; Ivan Sabolić; Hermann Koepsell
Journal:  Pflugers Arch       Date:  2014-10-11       Impact factor: 3.657

Review 6.  Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies.

Authors:  Chrishan J A Ramachandra; Jasper Chua; Shuo Cong; Myu Mai Ja Kp; Winston Shim; Joseph C Wu; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2021-02-22       Impact factor: 10.787

7.  New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans.

Authors:  Laura Ferté; Alice Marino; Sylvain Battault; Laurent Bultot; Anne Van Steenbergen; Anne Bol; Julien Cumps; Audrey Ginion; Hermann Koepsell; Laure Dumoutier; Louis Hue; Sandrine Horman; Luc Bertrand; Christophe Beauloye
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-01-08       Impact factor: 4.733

8.  Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice.

Authors:  Yusuke Kashiwagi; Tomohisa Nagoshi; Takuya Yoshino; Toshikazu D Tanaka; Keiichi Ito; Tohru Harada; Hiroyuki Takahashi; Masahiro Ikegami; Ryuko Anzawa; Michihiro Yoshimura
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

9.  Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.

Authors:  Mohun Ramratnam; Ravi K Sharma; Stephen D'Auria; So Jung Lee; David Wang; Xue Yin N Huang; Ferhaan Ahmad
Journal:  J Am Heart Assoc       Date:  2014-08-04       Impact factor: 5.501

Review 10.  New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.

Authors:  Dirk von Lewinski; Ewald Kolesnik; Markus Wallner; Michael Resl; Harald Sourij
Journal:  Biomed Res Int       Date:  2017-08-15       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.